<DOC>
	<DOCNO>NCT00081809</DOCNO>
	<brief_summary>Primary Objectives : - To document efficacy treatment autologous lymphoma-derived HSPPC-96 select patient indolent lymphoma . The efficacy endpoint : - rate complete partial response - time progression . Secondary Objectives : - To evaluate safety tolerability autologous tumor-derived heat-shock protein peptide complex ( HSPPC-96 ) administer intradermally weekly four consecutive week , follow HSPPC-96 administer every two week . - To evaluate feasibility autologous HSPPC-96 preparation lymphoma specimen . - To assess approximately composition tissue source autologous HSPPC-96 patient . - To study effect autologous lymphoma-derived HSPPC-96 vaccine therapy expression Fas ligand TRAIL death proteins peripheral blood lymphocytes patient indolent lymphoma .</brief_summary>
	<brief_title>A Safety Effectiveness Study Vaccine Therapy Patients With Indolent Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Patients previously treat newly diagnose follicular center cell grade I grade II lymphoma , small lymphocytic lymphoma , MALT lymphoma , monocytoid Bcell lymphoma , Waldenstrom 's macroglobulinemia , marginal zone lymphoma bidimensionally measurable disease ; Part resect specimen must undergo routine pathologic examination confirm diagnosis lymphoma . The remain tissue must use preparation autologous HSPPC96 ; Autologous HSPPC96 vaccine must successfully prepare provided sponsor ; A minimum 2 gram nonnecrotic , resectable malignant lymphoma HSPPC96 preparation ; Bidimensionally measurable disease least one location resect lymphoid tissue ; Life expectancy least 16 week ; Zubrod performance status less equal 2 ; Adequate bone marrow function ; Adequate hepatic function ; Adequate renal function ; Signed write informed consent ; Patients childbearing potential must practice contraception , adequate opinion Principal Investigator ; Patients childbearing potential must negative serum pregnancy test prior entry study must lactate ; Patients must willing follow M. D. Anderson Cancer Center course treatment followup ; Electrocardiogram none perform prior six month ; Patients must chemotherapy , immunotherapy , radiotherapy , experimental anticancer therapy within six week prior start autologous HSPPC96 administration ; Patients must fully recover prior anticancer therapy ; Tumor measurement stag 4 week prior receive first dose autologous HSPPC96 . Patients active prior history central nervous system lymphoma ; Patients serious intercurrent medical illness , require hospitalization ; Patients history primary secondary immunodeficiency ( related malignant lymphoma treatment dependent functional immune system ) patient take immunosuppressive drug systemic corticosteroid ; Women pregnant lactating ; Patients participate another clinical trial ; Patients receive growth factor kind , include GCSF , GMCSF , Epogen ; Patients bulky disease , define great 10 cm diameter ; Patients positive HIV antibody ; Patients 4 previous treatment regimen exclude .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>non-Hodgkin 's lymphoma</keyword>
	<keyword>Brill-Symmers Disease</keyword>
	<keyword>Follicular Lymphoma</keyword>
	<keyword>Lymphoma , Giant Follicular</keyword>
	<keyword>Lymphoma , Nodular</keyword>
	<keyword>Follicular Lymphoma , Giant</keyword>
	<keyword>Giant Follicular Lymphoma</keyword>
	<keyword>Lymphocytic Lymphoma , Diffuse , Well-Differentiated</keyword>
	<keyword>Lymphocytic Lymphoma , Well-Differentiated</keyword>
	<keyword>Lymphoma , Lymphocytic , Diffuse , Well-Differentiated</keyword>
	<keyword>Lymphoma , Lymphocytic , Well-Differentiated</keyword>
	<keyword>Lymphoma , Lymphoplasmacytoid , CLL</keyword>
	<keyword>Lymphoma , Small Lymphocytic , Plasmacytoid</keyword>
	<keyword>Lymphoplasmacytoid Lymphoma , CLL</keyword>
	<keyword>Diffuse Well-Differentiated Lymphocytic Lymphoma</keyword>
	<keyword>Lymphocytic Lymphoma , Diffuse , Well Differentiated</keyword>
	<keyword>Lymphocytic Lymphoma , Well Differentiated</keyword>
	<keyword>Lymphoma , Lymphocytic , Diffuse , Well Differentiated</keyword>
	<keyword>Lymphoma , Lymphocytic , Well Differentiated</keyword>
	<keyword>Lymphoma , Mucosa-Associated Lymphoid Tissue</keyword>
	<keyword>MALT Lymphoma</keyword>
	<keyword>Lymphoma Mucosa-Associated Lymphoid Tissue</keyword>
	<keyword>Mucosa-Associated Lymphoid Tissue Lymphoma</keyword>
	<keyword>Monocytoid B-cell lymphoma</keyword>
	<keyword>Waldenstrom 's macroglobulinemia</keyword>
	<keyword>Marginal zone lymphoma</keyword>
</DOC>